Vera Therapeutics, Inc. (NASDAQ: VERA) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Vera Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $26.20, Vera Therapeutics, Inc. trades at 183.7x sales and 5.7x book value. Over the last twelve months it generated about $10M of revenue and a net loss of $428M. It runs a gross margin of 67.9%, an operating margin of -4160.1% and a net margin of -4041.2%. It shows return on equity of -90.0%, return on invested capital of -104.3% and a free cash flow yield of -19.9%. On the balance sheet: a debt-to-equity ratio of 0.23 and a current ratio of 7.91. Over the past 52 weeks the share price ranged from $25.82 to $56.05, with a beta of 0.95.
Vera Therapeutics, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 1 Strong Buy, 12 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.